在印度瓦多达拉的糖尿病患者中使用食补充剂:一个横截面研究
Anupriya Mamgain1, Swati Dhruv1
1Department of Foods and Nutrition, Faculty of Family and Community Sciences, The Maharaja Sayajirao University of Baroda, Vadodara, India.
Nutrition and health
|May 21, 2025
概括
在印度的糖尿病患者中观察到饮食补充剂的使用率很高,菜是常见的选择. 许多患者不向医生披露这种使用情况,强调需要更安全地纳入糖尿病护理.
科学领域:
- 综合医学是一个整体的医学.
- 内分泌学 在内分泌学.
- 公共卫生 公共卫生
背景情况:
- 补充和替代医学 (CAM),包括草药和阿育吠陀,被广泛用于疾病管理.
- 食补充剂是CAM中的一个重要类别,慢性病患者对其越来越感兴趣.
研究的目的:
- 确定糖尿病患者中饮食补充剂使用的流行率和模式.
- 为了确定与饮食补充剂在这个人群中的使用相关的因素.
主要方法:
- 一项涉及400名成人糖尿病患者的横截面研究在印度古吉拉特州瓦多达拉进行.
- 关于饮食补充剂消费的数据是通过面对面的采访收集的.
主要成果:
- 62%的糖尿病患者报告使用食补充剂,40.72%的人停止使用.
- 草种子是用于糖尿病管理的最常见的补充剂.
- 年龄,糖尿病持续时间,家族病史和其他慢性疾病等因素与补充剂使用有关.
- 大约三分之二的患者没有向医疗保健提供者披露他们补充剂的使用情况.
结论:
- 饮食补充剂的使用在糖尿病患者中非常普遍.
- 研究结果强调需要进一步的研究和政策制定,以确保饮食补充剂安全地纳入糖尿病治疗.
相关概念视频
Diabetes Mellitus: Overview and Type I Subtype
2.3K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.3K
Diabetes Mellitus: Type 2 and Gestational
2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K
Diabetes: Symptoms, Diagnosis, and Complications
495
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
495
Diabetes: Management and Pharmacotherapy
220
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
220
Oral Hypoglycemic Agents: Sulfonylureas
175
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
175
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
140
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
140
